SCHEMBL19862565

SCHEMBL19862565

CCc1ccc(CNC(C)C)nc1

nearest known ligand 0.47

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
HRH3 Q9Y5N1 3/20 0.47
CYP1A2 P05177 1/20 0.46
CYP2D6 P10635 1/20 0.46
KMT2A Q03164 2/20 0.39
MEN1 O00255 1/20 0.39
LMNA P02545 1/20 0.39
POLB P06746 2/20 0.38
KDM4E B2RXH2 2/20 0.38
L3MBTL1 Q9Y468 2/20 0.38
CXCR4 P61073 2/20 0.35
CD274 Q9NZQ7 1/20 0.35
NPC1 O15118 1/20 0.34
RAB9A P51151 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
ALDH1A1 P00352 1/20 0.33
NPSR1 Q6W5P4 1/20 0.33
MAPT P10636 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30707864 0.81 ALDH1A1 (0.43) HRH3CYP1A2CYP2D6KMT2AMEN1
SCHEMBL19580586 0.79 HRH3 (0.47) HRH3CYP1A2CYP2D6KMT2AMEN1
SCHEMBL30707740 0.79 LMNA (0.42) HRH3CYP1A2CYP2D6KMT2AMEN1
SCHEMBL13952470 0.79 HRH3 (0.39) HRH3CYP1A2CYP2D6KMT2AMEN1
SCHEMBL19862555 0.78 CCR1 (0.40) KDM4ECXCR4RAB9AALDH1A1MAPT
SCHEMBL18089386 0.78 HRH3 (0.46) HRH3CYP1A2CYP2D6KMT2AMEN1
SCHEMBL19862558 0.76 KCNH2 (0.39)
SCHEMBL15240118 0.76 GBA1 (0.42) KDM4ENPC1RAB9ASMN1; SMN2ALDH1A1
SCHEMBL19862557 0.76 L3MBTL1 (0.38) KMT2AMEN1L3MBTL1NPC1RAB9A
SCHEMBL30398570 0.76 HRH3 (0.55) HRH3CYP1A2CYP2D6KMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180044343-A1 BICYCLIC IMIDAZOLO DERIVATIVE SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) 2018-02-15 US disclosed
US-20180044343-A1 BICYCLIC IMIDAZOLO DERIVATIVE SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) 2018-02-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180044343-A1 BICYCLIC IMIDAZOLO DERIVATIVE PDE3A, PDE2A, PDE5A HRH3 4261/4885CYP1A2 677/4885CYP2D6 1605/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.